These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 32663067)

  • 1. Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany.
    Augustin M; Wirth D; Mahlich J; Pepper AN; Druchok C
    J Dermatolog Treat; 2022 Mar; 33(2):976-982. PubMed ID: 32663067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany.
    Nyholm N; Schnack H; Danø A; Skowron F
    Curr Med Res Opin; 2023 Jun; 39(6):833-842. PubMed ID: 37203343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost per response for guselkumab versus adalimumab in the United States using data from a head-to-head trial in moderate-to-severe plaque psoriasis.
    Teeple A; Muser E
    J Med Econ; 2019 Dec; 22(12):1268-1273. PubMed ID: 31199173
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost per responder for guselkumab versus secukinumab in the United States based on a head-to-head trial of moderate to severe plaque psoriasis.
    Teeple A; Fitzgerald T
    J Dermatolog Treat; 2022 Feb; 33(1):518-524. PubMed ID: 32479140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Brodalumab for Moderate to Severe Plaque Psoriasis: A Canadian Network Meta-Analysis.
    Xue W; Saharia P; Gray E; Khoudigian-Sinani S; Gaudet V; Barbeau M; Papp K
    J Cutan Med Surg; 2020; 24(6):561-572. PubMed ID: 32588642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
    Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
    J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost per additional responder for ixekizumab and other FDA-approved biologics in moderate-to-severe plaque psoriasis.
    Al Sawah S; Foster SA; Burge R; Amato D; Schacht A; Zhu B; Hartz S; Leonardi C
    J Med Econ; 2017 Dec; 20(12):1224-1230. PubMed ID: 28760056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimate of the cost per responder for treatment with biological therapies of moderate-to-severe plaque psoriasis in Colombia for first-year and maintenance periods.
    Lasalvia P; Gil-Rojas Y; Papadimitropoulos E; Burge R; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2023 Jun; 23(5):511-517. PubMed ID: 36927221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.
    Imafuku S; Nakano A; Dakeshita H; Li J; Betts KA; Guerin A
    J Dermatolog Treat; 2018 Feb; 29(1):24-31. PubMed ID: 28608740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
    Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
    J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
    Griffiths CEM; Papp KA; Kimball AB; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
    J Drugs Dermatol; 2018 Aug; 17(8):826-832. PubMed ID: 30124721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bai F; Li GG; Liu Q; Niu X; Li R; Ma H
    J Immunol Res; 2019; 2019():2546161. PubMed ID: 31583255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.
    Armstrong AW; Betts KA; Signorovitch JE; Sundaram M; Li J; Ganguli AX; Wu EQ
    Curr Med Res Opin; 2018 Jul; 34(7):1325-1333. PubMed ID: 29619856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost per cumulative clinical benefit of biologic therapies for patients with plaque psoriasis: a systematic review.
    Blauvelt A; Burge R; Malatestinic W; Brnabic A; Guo J; Janardhanan M; Zhu B
    J Manag Care Spec Pharm; 2021 Jan; 27(1):84-94. PubMed ID: 33377444
    [No Abstract]   [Full Text] [Related]  

  • 17. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
    Puig L; Wu JJ; Gooderham MJ; You Y; Shen YK; Randazzo B; Kerdel F
    J Dermatolog Treat; 2021 Aug; 32(5):484-491. PubMed ID: 31613178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
    Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
    Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study.
    Blauvelt A; Armstrong AW; Langley RG; Gebauer K; Thaçi D; Bagel J; Guenther LC; Paul C; Randazzo B; Flavin S; Hsu MC; You Y; Reich K
    J Dermatolog Treat; 2022 Jun; 33(4):2317-2324. PubMed ID: 34348574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
    Gordon KB; Armstrong AW; Han C; Foley P; Song M; Wasfi Y; You Y; Shen YK; Reich K
    J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1940-1949. PubMed ID: 29706008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.